AspenBio to Provide Investors with Clinical and Business Update

       AspenBio to Provide Investors with Clinical and Business Update

Conference Call and Webcast scheduled for September 27, 2012, 8:30 a.m. ET

PR Newswire

CASTLE ROCK, Colo., Sept. 25, 2012

CASTLE ROCK, Colo., Sept. 25, 2012 /PRNewswire/ --AspenBio Pharma, Inc.
(Nasdaq: APPY), an in vitro diagnostic company, today announced that it will
host a conference call and live audio webcast on Thursday, September 27, 2012,
at 8:30 a.m. ET to provide its shareholders and the broader investment
community with an update on the Company's recent clinical and business

Interested participants and investors may access the conference call by
dialing 800-860-2442 (U.S.); 866-605-3852 (Canada); or 412-858-4600
(international). An audio webcast will be accessible via the Investors
Relations section of the AspenBio web site,

A telephonic replay of the call will be available for two weeks beginning at
9:30 a.m. ET on September 27, 2012. Access numbers for this replay are
877-344-7529 (U.S./Canada) and 412-317-0088 (international); conference ID:
10018947. The webcast replay will remain available in the Investors Relations
section of the AspenBio web site for 30 days.

About AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the
clinical development and commercialization of its lead product, AppyScore.
AppyScore is a unique blood-based test with projected high sensitivity and
negative predictive value that is designed to aid in the identification of
patients at low risk for acute appendicitis, allowing for more conservative
patient management. AppyScore is initially being developed for pediatric,
adolescent and young adult patients with abdominal pain as this population is
at the highest risk for appendicitis as well having the highest risk of the
long-term health effects associated with CT imaging. For more information,

Forward-Looking Statements
This press release includes "forward-looking statements" of AspenBio Pharma,
Inc. ("AspenBio") as defined by the Securities and Exchange Commission
("SEC"). All statements, other than statements of historical fact, included in
this press release that address activities, events or developments that
AspenBio believes or anticipates will or may occur in the future are
forward-looking statements. These statements are based on certain assumptions
made based on experience, expected future developments and other factors
AspenBio believes are appropriate in the circumstances. Such statements are
subject to a number of assumptions, risks and uncertainties, many of which are
beyond the control of AspenBio. Investors are cautioned that any such
statements are not guarantees of future performance. Actual results or
developments may differ materially from those projected in the forward-looking
statements as a result of many factors, including our ability to successfully
complete required product development and modifications in a timely and cost
effective manner, complete clinical trial activities for AppyScore required
for FDA submission, obtain FDA clearance or approval, complete and obtain CE
Mark, cost effectively manufacture and generate revenues from AppyScore,
execute agreements required to successfully advance the company's objectives,
retain the management team to advance the products, overcome adverse changes
in market conditions and the regulatory environment, obtain and enforce
intellectual property rights, and realize value of intangible assets.
Furthermore, AspenBio does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this press release
should be considered in conjunction with the risk factors contained in
AspenBio's recent filings with the SEC, including its Final Prospectus filed
on June 20, 2012.

For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020

SOURCE AspenBio Pharma, Inc.

Press spacebar to pause and continue. Press esc to stop.